期刊
EPIDEMIOLOGY
卷 27, 期 4, 页码 586-593出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/EDE.0000000000000480
关键词
-
资金
- Danish Cancer Society [R73-A4284-13-S17]
- Aarhus University Research Foundation
- Program for Clinical Research Infrastructure (PROCRIN)
- Elvira & Rasmus Riisforts Fonden
- Lundbeck Foundation [R167-2013-15861]
- Susan G. Komen for the Cure [CCR 13264024]
- Mary Kay Foundation [003-14]
- US National Cancer Institute at the National Institutes of Health [R01CA166825]
- Lundbeck Foundation [R167-2013-15861, R155-2014-2647] Funding Source: researchfish
- Novo Nordisk Fonden [NNF14SA0015794] Funding Source: researchfish
- The Danish Cancer Society [R73-A4284] Funding Source: researchfish
Background: Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients. We investigated the association of aspirin, NSAIDs, and use of selective COX-2 inhibitors with breast cancer recurrence. Methods: We identified incident stage I-II Danish breast cancer patients in the Danish Breast Cancer Cooperative Group registry, who were diagnosed during 1996-2008. Prescriptions for aspirin (>99% low-dose aspirin), NSAIDs, and selective COX-2 inhibitors were ascertained from the National Prescription Registry. Follow-up began on the date of breast cancer primary surgery and continued until the first of recurrence, death, emigration, or 1 January 2013. We used Cox regression models to compute hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) associating prescriptions with recurrence, adjusting for confounders. Results: We identified 34,188 breast cancer patients with 233,130 person-years of follow-up. Median follow-up was 7.1 years; 5,325 patients developed recurrent disease. Use of aspirin, NSAIDs, or selective COX-2 inhibitors was not associated with the rate of recurrence (HRadjusted aspirin = 1.0, 95% CI = 0.90, 1.1; NSAIDs = 0.99, 95% CI = 0.92, 1.1; selective COX-2 inhibitors = 1.1, 95% CI = 0.98, 1.2), relative to nonuse. Prediagnostic use of the exposure drugs was associated with reduced recurrence rates (HRaspirin = 0.92, 95% CI = 0.82, 1.0; HRNSAIDs = 0.86, 95% CI = 0.81, 0.91; HRsCOX-2inhibitors = 0.88, 95% CI = 0.83, 0.95). Conclusions: This prospective cohort study suggests that post diagnostic prescriptions for aspirin, NSAIDs, and selective COX-2 inhibitors have little or no association with the rate of breast cancer recurrence. Prediagnostic use of the drugs was, however, associated with a reduced rate of breast cancer recurrence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据